Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Marijana Virijevic
Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia
Teodora Karan-Djurasevic
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia
Irena Marjanovic
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia
Natasa Tosic
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia
Mirjana Mitrovic
Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia
Medical Faculty, University of Belgrade, Belgrade, Serbia
Irena Djunic
Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia
Medical Faculty, University of Belgrade, Belgrade, Serbia
Natasa Colovic
Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia
Medical Faculty, University of Belgrade, Belgrade, Serbia
Ana Vidovic
Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia
Medical Faculty, University of Belgrade, Belgrade, Serbia
Nada Suvajdzic-Vukovic
Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia
Medical Faculty, University of Belgrade, Belgrade, Serbia
Dragica Tomin
Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia
Medical Faculty, University of Belgrade, Belgrade, Serbia
Sonja Pavlovic
Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia